Spots Global Cancer Trial Database for A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Official Title: A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Study ID: NCT05848843

Conditions

Lung Cancer

Gastro-intestinal Cancer

Interventions

Durvalumab

Adagrasib

Study Description

Brief Summary: To find a recommended dose of the combination of adagrasib and durvalumab that can be given to patients with cancers that have a KRAS G12C mutation.

Detailed Description: Primary Objectives: • To determine the safety and tolerability, and to establish the recommended dose of the adagrasib and durvalumab combination in advanced NSCLC or GI cancer patients. Secondary Objectives: * To determine the objective response rate of the adagrasib and durvalumab combination for frontline treatment of advanced NSCLC harboring a KRAS G12C mutation. * To determine the objective response rate of the adagrasib and durvalumab combination for treatment of advanced CRC that have progressed on prior therapy with KRAS G12C inhibitors. * To determine duration of response (DOR) and progression-free survival (PFS) for the combination of the adagrasib and durvalumab in patients with advanced NSCLC harboring a KRAS G12C mutation. * To determine DOR and PFS for the combination of the adagrasib and durvalumab in patients with advanced CRC that have progressed on prior therapy with KRAS G12C inhibitors. Exploratory Objectives: * To assess predictive biomarkers of response and resistance to the combination of adagrasib and durvalumab. * To assess mechanisms of tumor cell adaptation upon treatment with the combination of adagrasib and durvalumab. * To determine mechanisms of acquired resistance to the combination of adagrasib and durvalumab. * To assess the effect of the combination of adagrasib and durvalumab on the immune tumor microenvironment. * To generate cell lines and patient derived xenograft (PDX) models from tumor samples. * To assess the anti-tumor reactivity of tumor infiltrating lymphocytes (TIL) from tumor biopsies.